FDA letter supports use of new alpha-synuclein assay in trials
The U.S. Food and Drug Administration (FDA) is encouraging scientists and drug developers to use an alpha-synuclein seed amplification assay (synSAA) to improve the development and efficiency of clinical trials seeking to delay or prevent the development of Parkinson’s and other neurodegenerative diseases that share toxic clumps of that protein…